ChromoGenics AB (publ): Bulletin from the Extraordinary General Meeting on 5 April 2024
ChromoGenics AB (publ) (the "Company") has today, on 5 April 2024, held an Extraordinary General Meeting. The Extraordinary General Meeting resolved to approve the Board of Directors' resolutions on directed issues of shares and there with related proposals. The notice to the Extraordinary General Meeting and the complete proposals are available on the Company's website, www.chromogenics.com.
Directed share issues and there with related resolutions
The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the Board of Directors' resolution on 5 March 2024 on a directed issue of a maximum of 2,493,787 shares to Färna Invest AB, Parment Förvaltning AB, Investment Aktiebolaget Balticum and Barbro Brandt, at a subscription price of SEK 6.44 per share, whereby the Company's share capital will increase by not more than SEK 13,715,828.50.
The Extraordinary General Meeting further resolved, in accordance with the Board of Directors' proposal to approve the Board of Directors' resolution on 5 March 2024, to issue a total of 12,098 shares to Johan Hedin, Anders Brännström, Fredrik Fränding, Fredrik Andersson, and Andreas Jaeger, at a subscription price of SEK 6.44 per share, whereby the Company's share capital will increase by not more than SEK 66,539.00.
The Extraordinary General Meeting further resolved, in accordance with the Board of Directors' proposal, to:
- amend the share capital limits in the Company's articles of association; and
- reduce the share capital in order to decrease the quota value of the Company's shares.
All resolution were made with the required majority.
The Articles of Association's new limits for share capital
The Extraordinary General Meeting resolved that the limits for the share capital in the Company's Articles of Association shall be not less than SEK 22,000,000 and not more than SEK 88,000,000.
For more information, please contact:
Fredrik Fränding, CEO
Tel: +46(0)72 249 24 62
Email: [email protected]
About this information
The information was submitted for publication, through the agency of the contact persons set out above, on 5 April 2024 at 11.45 CEST.
About ChromoGenics
ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films. The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass. All products from ChromoGenics prioritize environmental and health aspects, focusing on eco-friendly materials, reduced energy consumption, increased access to daylight and views, and improved indoor comfort.
ChromoGenics' production facility in Uppsala has been partly financed through conditional loans from the Swedish Energy Agency. ChromoGenics' stock (CHRO) is listed on the Nasdaq First North Growth Market, with Vator Securities serving as the Certified Adviser.
